1. In Vivo
  2. >>Archive

Encore Orthopedics

Developing a full range of orthopedic products. Expects to be able to respond faster and more completely than large orthopedics companies to surgeons, managed care customers and group purchasers. Initial focus in total joint implants. Company anticipates sales in total joint implants can reach $60 million by 1998.

Internally developed Foundationprimary knee system. Launched knee system in US in 1993 and eight European countries in 1992. Expects launch...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Archive

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By Ashley Yeo

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.